Contact
As several leading Indian drugmakers are readying to launch the generic versions of Danish drug maker Novo Nordisk’s blockbuster weight-loss drug semaglutide in March next year, its price is expected to crash by as much as 80% from the prevailing rate, analysts told ET.
